Dr. Lichtman is Professor of Pathology at the Brigham and Women’s Hospital and Harvard Medical School, where he has been a staff anatomic pathologist and a principal investigator for over 35 years. His research has been in the fields of immunology and vascular biology. He is an expert on T cell biology, including trafficking, activation, and regulation by checkpoint inhibitors, and the role of T cell mediated immune responses in cardiovascular disease.
Assoc. Professor Rohit Joshi is a Medical Oncology Consultant working with GenesisCare at Calvary Central Districts Hospital and St Andrew's Hospital. He also works at the Lyell McEwin Hospital.
Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
Dr Goy is Physician in Chief for Hackensack Meridian Health Oncology Services and Chairman of John Theurer Cancer Center as well as Founding Chair of Oncology at the Hackensack Meridian Health School of Medicine and Professor of Medicine at Georgetown University in Washington, DC.
Jared TaeOh Chung is a co-founding Partner at Clairvoyant Ventures (since 2014) where he serves as a key member of the investment team. He manages and invests four private funds across 17 individual portfolios. His expertise is in deal sourcing, raising funds and other value creation activities.
Dr. Sung-wuk Kim is an entrepreneur, angel investor and accomplished inventor who has made significant contributions to advance drug development: receiving more than 30 patents in a broad range of areas which include formulation, biologics and small molecule drugs.
A clinical, scientific, and regulatory professional with over 25 years of experience in global clinical development and operations in the field of pharmaceutical and biologic development. Having managed international programs from early research phase through the U.S. Food & Drug Administration approval process. Originally from Australia, Dr. Gargosky leads our clinical development efforts.
An expert in the injury induced modulation of the immune system and analytic methods for cell characterization, Dr. Lederer is an Associate Professor in the Department of Surgery, Brigham and Women’s Hospital and Harvard Medical School and Director.
Frank Borriello, MD, PhD leads Alloplex Biotherapeutics Inc., a private Boston-based company he founded in 2016 based on an original and now patented concept, as Chief Executive Officer.